No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers

British Journal of Clinical Pharmacology, Supplement

Volumn 56, Issue 1, 2003, Pages 62-68

  Purkins, Lynn ^a   Wood, Nolan ^a   Kleinermans, Diane ^b   Love, Edward R ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b ERASME HOSPITAL   (Belgium)

^c KENT AND CANTERBURY HOSPITAL   (United Kingdom)

Author keywords

Indinavir; Pharmacokinetics; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; INDINAVIR; VORICONAZOLE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HALITOSIS; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VIRUS REPLICATION; VOMITING;

EID: 0344943282     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.02001.x     Document Type: Article

References (19)

1. Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531-533.
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36; 198-202.
3. Chandrasekar PH, Manavathu E. Voriconazole: a second-generation triazole. Drugs Today 2001; 37: 135-148.
4. Torre-Cisneros J, Gonzalez-Ruiz A, Hodges MR, Lutsar I. Voriconazole (VORI) for the treatment of S. apiospermum and S. prolificans infection. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 305, September 2000.
5. Perfect J, Gonzalez-Ruiz A, Lutsar I. Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens. In Program and Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, Abstract 303, September 2000.
6. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
7. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182.
8. Patterson BE, Coates PE. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F78, September 1995.
9. Patterson BE, Roffey S, Jezequel SG, Jones B. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstract F79, September 1995.
10. British HIV. Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
11. Panel on Clinical practices for the treatment of HIV. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, 2002. MMWR Recomm Rep 2002; 51: 1-55.
12. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20: 147-169.
13. Stopher DA, Gage R. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. J Chromatogr B Biomed Sci Appl 1997; 691: 441-448.
14. McCrea J, Wyss D, Stone J et al. Pharmacokinetic interaction between indinavir and rifampin. Clin Pharmacol Ther 1997; 61: 152.
15. Back DJ, Khoo SH, Gibbons SE, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 89S-96S.
16. Aarnoutse RE, Grintjes KJ, Telgt DS et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71: 57-67.
17. Crixivan®. Summary of product characteristics. Hoddesdon, UK: Merck Sharp and Dohme Ltd, Available at http://www.eudra.org/humandocs/PDFs/EPAR/ Crixivan/058996en4.pdf, last accessed 19 March 2003.
18. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-194.
19. De Wit S, Debier M, De Smet M et al. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42: 223-227.